Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma

Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma

APR-246 (Eprenetapopt/PRIMA-1<sup>Met</sup>) is a very potent anti-cancer drug in clinical trials and was initially developed as a p53 refolding agent. As an alternative mode of action, the elevation of reactive oxygen species (ROS) has been proposed. Through an in silico analysis, we in...

Full description

Bibliographic Details
Main Authors: Michael Müller, Lisa Rösch, Sara Najafi, Charlotte Gatzweiler, Johannes Ridinger, Xenia F. Gerloff, David T. W. Jones, Jochen Baßler, Sina Kreth, Sabine Stainczyk, Karen Frese, Benjamin Meder, Frank Westermann, Till Milde, Heike Peterziel, Olaf Witt, Ina Oehme
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
histone deacetylases
ROS
TP53
small molecule inhibitors
pediatric tumors of the nervous system
precision medicine
Online Access:https://www.mdpi.com/2072-6694/13/17/4476

Internet

https://www.mdpi.com/2072-6694/13/17/4476

Similar Items